U.K. scientists develop new test to catch drugs-cheats in sport

Scientists from three UK universities have developed a new test to catch drugs-cheats in sport.

Over the last 10 years, the GH-2004 team, which is based the University of Southampton, has been developing a test for Growth Hormone misuse in sport with funding from the World Anti-Doping Agency (WADA) and US Anti-Doping Agency and with support from UK Anti-Doping.

The test, developed by scientists at the University of Southampton, King's College London and University of Kent at Canterbury, is based on the measurement of two proteins in the blood, insulin-like growth factor-I and the amino terminal pro-peptide of type III collagen. Both of these proteins, which act as markers of growth hormone use, increase in response to Growth Hormone.

The test was used for the first time by King's College London analysts at the anti-doping laboratory for the London 2012 Olympic and Paralympic Games.

On 8 September 2012, the International Paralympic Committee announced that two powerlifters had received two year suspensions for Anti-Doping Rule Violations involving Growth Hormone following an adverse laboratory finding using the new markers test.

The case was a world first as some of the latest testing methods were used which were only introduced prior to London 2012. The new method is able to detect misuse of human growth hormone over a number of weeks, compared to previous methods used which only detected use over a shorter time period.

Richard Holt, Professor in Diabetes and Endocrinology at the University of Southampton and also a consultant in Diabetes at Southampton General Hospital, said, "We are pleased to have another effective and reliable means to catch cheats and help deter harmful drug misuse. There has been a tremendous amount of team work to develop this test and I am delighted that this dedication has finally succeeded. I would like to thank the World Anti-Doping Agency, US Anti-Doping and UK Anti-Doping for their support and trust in our work."

Professor David Cowan, Head of the Drug Control Centre at King's College London and Director of the anti-doping laboratory for the Games, said: "These findings prove that the years of research have been worthwhile. In partnership with the University of Southampton and Kent University, this has been one of the most complex scientific projects the Drug Control Centre at King's has been involved in. To be able to carry out this test at this year's Games is a huge achievement. It represents a big step forward in staying at the forefront of anti-doping science, to help deter drug misuse in sport."

Andy Parkinson, UK Anti-Doping Chief Executive, adds: "Continual improvement in testing science is fundamental to the global anti-doping movement, ensuring that sophisticated dopers are caught and those at a tipping point are deterred. I am delighted that this UK developed test, which my team has been closely involved with, was used at the 2012 Paralympic Games to such good effect."

WADA President John Fahey praised the test by saying: "The new test - which has been approved by WADA - was first introduced prior to the London 2012 Olympic Games, and we are confident that it will prove a significant tool in the fight against doping in sport.

"It will complement the test that has been in use since the 2004 Athens Olympic Games, the major difference being that the anti-doping community now has a much longer detection window to work with."

Source: University of Southampton

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation